Clinical development of the oral gonadotropin-releasing hormone antagonist elagolix
Kristof Chwalisz, M.D., Ph.D.
Affiliations
Kristof Chwalisz, M.D., Ph.D.
Reprint requests: Kristof Chwalisz, M.D., Ph.D., Department of Obstetrics, Gynecology, and Reproductive Biology, Michigan State University, Grand Rapids, Michigan.; Department of Obstetrics, Gynecology, and Reproductive Biology, Michigan State University, Grand Rapids, Michigan
Elagolix is the first oral gonadotropin-releasing hormone antagonist that entered clinical development and received regulatory approval for the management of women with endometriosis and heavy menstrual bleeding associated with uterine fibroids in combination with a hormonal add-back therapy. This mini review aims to summarize the key clinical studies that led to its regulatory approval.
